See more : DarkPulse, Inc. (DPLS) Income Statement Analysis – Financial Results
Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Maxeon Solar Technologies, Ltd. (MAXN) Income Statement Analysis – Financial Results
- One REIT, Inc. (3290.T) Income Statement Analysis – Financial Results
- Guan Chao Holdings Limited (1872.HK) Income Statement Analysis – Financial Results
- Aspire Global plc (ASPIRE.ST) Income Statement Analysis – Financial Results
- Dundee Corporation (DNDEF) Income Statement Analysis – Financial Results
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 881.71K | 3.94M | 36.14M | 4.82M | 2.44M | 1.91M | 648.38K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.17M | 1.49M | 1.64M | 98.27K | 89.60K | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 0.00 | 0.00 |
| Gross Profit | -31.17M | -1.49M | -757.53K | 3.84M | 36.05M | -43.79M | -23.60M | -13.53M | -5.24M | -1.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -85.92% | 97.50% | 99.75% | -908.11% | -967.09% | -707.60% | -808.21% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.17M | 16.14M | 36.45M | 98.27M | 89.60M | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 210.67K | 575.09 |
| General & Administrative | 13.91M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Selling & Marketing | -641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.27M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Other Expenses | -30.53M | -48.77K | 11.90M | 13.27M | 4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.91M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Cost & Expenses | 45.08M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Interest Income | 0.00 | 0.00 | 1.83K | 1.03K | 1.23M | 982.78K | 183.11K | 477.00 | 3.42K | 2.12K | 754.00 | 59.74 |
| Interest Expense | 2.92M | 2.13M | 1.83M | 1.03M | 19.03K | 0.00 | 183.11K | 0.00 | 2.44K | 24.02K | 45.11K | 0.00 |
| Depreciation & Amortization | 641.00K | 1.49M | 1.64M | 1.69M | 1.23M | 493.94K | 255.65K | 87.66K | 43.94K | 10.41K | 754.00 | 824.15 |
| EBITDA | -44.44M | -38.73M | -54.97M | -121.69M | -76.37M | -56.25M | -32.31M | -19.90M | -8.81M | -2.64M | -556.52K | -62.81 |
| EBITDA Ratio | 0.00% | 0.00% | -6,381.74% | -3,101.40% | -212.89% | -1,178.71% | -1,332.72% | -1,040.23% | -1,358.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.08M | -39.84M | -55.99M | -122.81M | -77.10M | -56.75M | -32.56M | -19.99M | -8.85M | -2.65M | -557.28K | -824.15 |
| Operating Income Ratio | 0.00% | 0.00% | -6,350.09% | -3,119.20% | -213.33% | -1,176.78% | -1,334.43% | -1,045.56% | -1,365.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 473.99K | -2.51M | 10.35M | 11.54M | 5.65M | 1.08M | 141.20K | -13.62K | 2.95K | 106.69K | -45.07K | -62.81 |
| Income Before Tax | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Income Before Tax Ratio | 0.00% | 0.00% | -5,176.38% | -2,826.08% | -197.69% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.49M | -87.84K | 35.05K | -2.30M | 1.08M | -396.86K | 13.62K | 2.44K | 24.02K | 44.36K | -62.81 |
| Net Income | -44.60M | -55.83M | -45.55M | -111.30M | -69.15M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Net Income Ratio | 0.00% | 0.00% | -5,166.42% | -2,826.97% | -191.33% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| EPS | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| EPS Diluted | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| Weighted Avg Shares Out | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.00 |
| Weighted Avg Shares Out (Dil) | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.16 |
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports